NASDAQ:PAVM PAVmed (PAVM) Stock Price, News & Analysis $0.77 +0.00 (+0.45%) As of 01:56 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About PAVmed Stock (NASDAQ:PAVM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get PAVmed alerts:Sign Up Key Stats Today's Range$0.72▼$0.7950-Day Range$0.59▼$0.8452-Week Range$0.57▼$2.84Volume68,914 shsAverage Volume106,345 shsMarket Capitalization$8.49 millionP/E RatioN/ADividend YieldN/APrice Target$19.00Consensus RatingStrong Buy Company OverviewPAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.Read More… Remove Ads PAVmed Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks81st Percentile Overall ScorePAVM MarketRank™: PAVmed scored higher than 81% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingStrong Buy Consensus RatingPAVmed has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoveragePAVmed has received no research coverage in the past 90 days.Read more about PAVmed's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for PAVmed are expected to grow in the coming year, from ($3.56) to ($2.33) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of PAVmed is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PAVmed is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about PAVmed's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.46% of the float of PAVmed has been sold short.Short Interest Ratio / Days to CoverPAVmed has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in PAVmed has recently increased by 21.41%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPAVmed does not currently pay a dividend.Dividend GrowthPAVmed does not have a long track record of dividend growth. Sustainability and ESG4.3 / 5Environmental Score-0.78 Percentage of Shares Shorted4.46% of the float of PAVmed has been sold short.Short Interest Ratio / Days to CoverPAVmed has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in PAVmed has recently increased by 21.41%, indicating that investor sentiment is decreasing significantly. News and Social Media1.8 / 5News Sentiment0.31 News SentimentPAVmed has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for PAVmed this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for PAVM on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, PAVmed insiders have not sold or bought any company stock.Percentage Held by Insiders11.30% of the stock of PAVmed is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 19.93% of the stock of PAVmed is held by institutions.Read more about PAVmed's insider trading history. Receive PAVM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PAVmed and its competitors with MarketBeat's FREE daily newsletter. Email Address PAVM Stock News HeadlinesLucid Diagnostics' ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed PublicationMarch 18 at 8:31 AM | prnewswire.comPAVmed (NASDAQ:PAVM) Shares Pass Below 50-Day Moving Average - Here's WhyMarch 15 at 3:41 AM | americanbankingnews.comLying in hospital… staring at the light"Please don’t die on me," the nurse begged as Porter Stansberry lay in a hospital bed, his heart stopped from years of pushing himself too hard. At his lowest point, he realized that everything had gone wrong, and he was forced to rebuild—not just his health, but his entire life and fortune. After clawing his way out of that abyss, Porter discovered a life-changing investment strategy, one that allowed him to rebuild his wealth far faster and with less risk than he ever imagined. This approach helped him earn enormous returns outside of the volatile stock market, and now he’s sharing it with you. While most won’t believe it’s possible, Porter is asking you to open your mind and consider a new way of investing—one that could transform your financial future, just as it did for him.March 18, 2025 | Porter & Company (Ad)Lucid Diagnostics Secures First Positive Commercial Insurance Coverage Policy for its EsoGuard® Esophageal DNA TestMarch 13, 2025 | prnewswire.comLucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 24, 2025March 10, 2025 | prnewswire.comLucid Diagnostics Announces Closing of $15.3 Million Registered Direct OfferingMarch 5, 2025 | prnewswire.comLucid Diagnostics to sell 13.94M shares at $1.10 in registered direct offeringMarch 4, 2025 | markets.businessinsider.comLucid Diagnostics Announces $15.3 Million Registered Direct OfferingMarch 4, 2025 | prnewswire.comSee More Headlines PAVM Stock Analysis - Frequently Asked Questions How have PAVM shares performed this year? PAVmed's stock was trading at $0.6275 on January 1st, 2025. Since then, PAVM shares have increased by 21.0% and is now trading at $0.7590. View the best growth stocks for 2025 here. How were PAVmed's earnings last quarter? PAVmed Inc. (NASDAQ:PAVM) issued its quarterly earnings data on Thursday, August, 12th. The company reported ($2.10) earnings per share for the quarter, missing the consensus estimate of ($1.50) by $0.60. When did PAVmed's stock split? PAVmed shares reverse split before market open on Thursday, December 7th 2023. The 1-15 reverse split was announced on Thursday, December 7th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, December 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. Who are PAVmed's major shareholders? Top institutional investors of PAVmed include First Manhattan CO. LLC. (6.32%) and Concourse Financial Group Securities Inc.. View institutional ownership trends. How do I buy shares of PAVmed? Shares of PAVM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of PAVmed own? Based on aggregate information from My MarketBeat watchlists, some other companies that PAVmed investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), CrowdStrike (CRWD), Pfizer (PFE). Company Calendar Last Earnings8/12/2021Today3/18/2025Next Earnings (Estimated)3/25/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNASDAQ:PAVM CIK1624326 Webwww.pavmed.com Phone(212) 949-4319FaxN/AEmployees90Year FoundedN/APrice Target and Rating Average Stock Price Target$19.00 High Stock Price Target$19.00 Low Stock Price Target$19.00 Potential Upside/Downside+2,440.1%Consensus RatingStrong Buy Rating Score (0-4)3.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($4.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-64,180,000.00 Net Margins602.97% Pretax Margin244.87% Return on EquityN/A Return on Assets-92.36% Debt Debt-to-Equity RatioN/A Current Ratio0.06 Quick Ratio0.06 Sales & Book Value Annual Sales$4.03 million Price / Sales2.05 Cash FlowN/A Price / Cash FlowN/A Book Value($3.35) per share Price / Book-0.22Miscellaneous Outstanding Shares11,069,000Free Float9,818,000Market Cap$8.28 million OptionableOptionable Beta1.19 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:PAVM) was last updated on 3/18/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredLying in hospital… staring at the light"Please don’t die on me," the nurse begged as Porter Stansberry lay in a hospital bed, his heart stopped from ...Porter & Company | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredIs this the End of the AI Boom?If you’re worried about all the recent volatility in the market… Or if you have any money in AI stocks… ...Brownstone Research | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredTrump Orders 'National Digital Asset Stockpile'Trump Orders ‘National Digital Asset Stockpile’ THIS could be the coin they choose…Crypto 101 Media | SponsoredTitanic SyndromeStocks are experiencing a pattern known as the "Titanic Syndrome." I'm talking about the dramatic jump in t...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PAVmed Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PAVmed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.